EUGENIE S KLEINERMAN to Osteosarcoma
This is a "connection" page, showing publications EUGENIE S KLEINERMAN has written about Osteosarcoma.
Connection Strength
11.996
-
Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology. 2020; 9(1):1747677.
Score: 0.422
-
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020; 1257:181-192.
Score: 0.414
-
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Adv Exp Med Biol. 2020; 1258:177-187.
Score: 0.414
-
Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 2018 06; 7(6):2654-2664.
Score: 0.369
-
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Mol Cancer Ther. 2018 06; 17(6):1315-1323.
Score: 0.366
-
miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases. Mol Cancer Ther. 2018 01; 17(1):130-139.
Score: 0.356
-
Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps? Lancet Oncol. 2016 10; 17(10):1340-1342.
Score: 0.328
-
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014 Aug; 61(8):1362-8.
Score: 0.277
-
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Adv Exp Med Biol. 2014; 804:203-17.
Score: 0.273
-
Osteosarcoma: the state of affairs dictates a change. What do we know? Adv Exp Med Biol. 2014; 804:vii-viii.
Score: 0.273
-
Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer. 2013 Oct 26; 13:500.
Score: 0.270
-
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer. 2014 Apr; 61(4):618-26.
Score: 0.269
-
The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets. 2013 May; 13(4):411-22.
Score: 0.261
-
Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression. Curr Cancer Drug Targets. 2013 Jan; 13(1):48-56.
Score: 0.255
-
Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatr Blood Cancer. 2013 Apr; 60(4):575-9.
Score: 0.254
-
miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012 Feb 15; 72(4):908-16.
Score: 0.237
-
Genetically modified T cells targeting interleukin-11 receptor a-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012 Jan 01; 72(1):271-81.
Score: 0.235
-
Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer. 2011 Aug 01; 117(15):3457-67.
Score: 0.223
-
Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010 Aug; 23(4):189-96.
Score: 0.215
-
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res. 2010 Aug 01; 16(15):4024-30.
Score: 0.214
-
Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. Oncol Res. 2009; 18(1):31-9.
Score: 0.193
-
The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res. 2009; 152:497-508.
Score: 0.193
-
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 2008 Jul; 30(7):507-12.
Score: 0.187
-
The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells. Mol Cancer Res. 2008 Jan; 6(1):119-26.
Score: 0.180
-
VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. J Exp Ther Oncol. 2008; 7(2):89-97.
Score: 0.180
-
Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007 Oct; 5(10):991-9.
Score: 0.177
-
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4503-10.
Score: 0.175
-
Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer. 2006 Mar 15; 106(6):1382-8.
Score: 0.159
-
Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res. 2005 Dec; 3(12):685-91.
Score: 0.156
-
Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol. 2005 Nov; 27(11):611-5.
Score: 0.155
-
Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005 Sep 01; 116(3):458-63.
Score: 0.153
-
Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res. 2005 Feb 15; 65(4):1124-8.
Score: 0.148
-
Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res. 2004 Dec 01; 10(23):8114-9.
Score: 0.146
-
Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway. Clin Cancer Res. 2004 Jan 15; 10(2):777-83.
Score: 0.137
-
Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis. 2004; 21(8):747-53.
Score: 0.137
-
Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res. 2003 Aug 15; 9(9):3462-8.
Score: 0.133
-
Nude mouse lung metastases models of osteosarcoma and Ewing's sarcoma for evaluating new therapeutic strategies. Methods Mol Med. 2003; 74:495-505.
Score: 0.127
-
Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep. 2002 Jul-Aug; 9(4):823-7.
Score: 0.123
-
Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 2002 Mar; 9(3):260-6.
Score: 0.120
-
Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drugs. 2002 Feb; 13(2):155-61.
Score: 0.120
-
Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. J Exp Ther Oncol. 2002 Jan-Feb; 2(1):27-36.
Score: 0.119
-
Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity. Cancer Med. 2021 11; 10(21):7572-7584.
Score: 0.116
-
Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features. Apoptosis. 2021 08; 26(7-8):447-459.
Score: 0.114
-
Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res. 2001 May 15; 61(10):4066-71.
Score: 0.114
-
Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. Int J Cancer. 2021 04 15; 148(8):1928-1937.
Score: 0.110
-
Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res. 2000 Sep; 6(9):3713-8.
Score: 0.108
-
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells. J Immunother Cancer. 2020 04; 8(1).
Score: 0.105
-
Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res. 1999 Jun; 19(6):617-24.
Score: 0.099
-
Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. J Adolesc Young Adult Oncol. 2019 06; 8(3):385-386.
Score: 0.098
-
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
Score: 0.097
-
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999; 17(6):501-6.
Score: 0.097
-
Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res. 1997 Oct; 3(10):1721-9.
Score: 0.089
-
BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proc Natl Acad Sci U S A. 2017 07 25; 114(30):8065-8070.
Score: 0.087
-
Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.083
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am. 1995 Aug; 9(4):927-38.
Score: 0.076
-
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol. 1995 Apr; 17(3):181-93.
Score: 0.074
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr; 18(2):93-9.
Score: 0.074
-
Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014 Aug 15; 20(16):4200-9.
Score: 0.070
-
Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):286-92.
Score: 0.067
-
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer. 2014 Feb; 61(2):238-44.
Score: 0.067
-
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:101-7.
Score: 0.064
-
MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis. 2012 Aug 09; 3:e369.
Score: 0.062
-
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992 Aug; 10(8):1310-6.
Score: 0.062
-
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992; 34(4):211-20.
Score: 0.059
-
Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines. Lymphokine Cytokine Res. 1991 Aug; 10(4):281-4.
Score: 0.058
-
Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol. 1991 Feb; 9(2):259-67.
Score: 0.056
-
Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv. 2010 Aug; 23(4):197-206.
Score: 0.054
-
Liposomal MTP-PE for the adjuvant therapy of osteosarcoma. Prog Clin Biol Res. 1990; 343:263-79.
Score: 0.052
-
Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer. 2009 Dec 01; 125(11):2586-94.
Score: 0.051
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009 Nov 15; 115(22):5339-48.
Score: 0.051
-
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
Score: 0.050
-
In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res. 1988 Sep 15; 48(18):5256-63.
Score: 0.047
-
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 01; 26(4):633-8.
Score: 0.045
-
Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer. 2008 Jan 23; 7:9.
Score: 0.045
-
Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol. 2007 Dec; 29(12):815-21.
Score: 0.045
-
Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy. J Neurooncol. 1986; 4(2):165-7.
Score: 0.039
-
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11.
Score: 0.037
-
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15; 9(15):5442-53.
Score: 0.034
-
Alpha 4 integrin increases anoikis of human osteosarcoma cells. J Cell Biochem. 2003 Apr 01; 88(5):1038-47.
Score: 0.032
-
Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 2001 Sep; 8(9):619-27.
Score: 0.029
-
Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001 Aug; 15(4):723-40, ix.
Score: 0.029
-
9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res. 2000 Jul; 6(7):2876-80.
Score: 0.027
-
ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother. 1999 Sep; 48(6):312-20.
Score: 0.025
-
Osteosarcoma metastatic to the pancreas in young patients. Clin Radiol. 1996 Apr; 51(4):293-4.
Score: 0.020
-
Liposomal MTP-PE. J Pediatr Oncol Nurs. 1994 Oct; 11(4):161-3.
Score: 0.018
-
Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Trans Am Clin Climatol Assoc. 2000; 111:135-45.
Score: 0.006
-
9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci. 2000; 922:151-63.
Score: 0.006